RESUMO
AIM: To perform a comparative study of the results of optical coherence tomography of the retina in patients with relapsing-remitting multiple sclerosis, treated with glatiramer acetate (timexon). MATERIAL AND METHODS: The study included 19 patients (16 women and 3 men) with relapsing-remitting multiple sclerosis who were treated with the glatiramer acetate generic drug timexon (BIOCAD, Russia). Dynamic changes in the main parameters of the optical coherence tomography linked with neurodegeneration manifestations in the retina during the year of the study were evaluated. RESULTS AND CONCLUSION: The efficacy of timexon in the progression of neurodegenerative changes in the retina was shown.
Assuntos
Esclerose Múltipla Recidivante-Remitente , Feminino , Acetato de Glatiramer , Humanos , Masculino , Retina , Federação RussaRESUMO
AIM: For a long time it was believed that pregnancy worsens the clinical course of multiple sclerosis. In several European countries, there have been several studies that have demonstrated remission of autoimmune aggression during pregnancy. We studied the effect of pregnancy on the course of multiple sclerosi. MATERIAL AND METHODS: A retrospective analysis of disease course of 279 patients was performed for the first time in three major Russian centers (Moscow, Novosibirsk, Tyumen). RESULTS AND CONCLUSION: There was a remission of autoimmune aggression during pregnancy. The use of DMT before pregnancy was a predictor of a more favorable course of the disease after delivery. An earlier beginning of DMT after delivery led to a significant risk reduction of relapses.
RESUMO
A total of 326 patients with multiple sclerosis (MS) according to the McDonald criteria (2005) were recruited to the study. Single nucleotide polymorphisms in the CD40 gene (rs6074022, rs1883832, rs1535045 and rs11086998) and the KIF1B gene (rs10492972 and rs3135388) were genotyped using TaqMan technology. We found a significant association of rs1883832 (risk allele T, OR=1.74, 95% CI 1.34-2.32, p=2.96·10-7) and rs3135388 (risk allele T, OR=3.23, 95% CI 2.43-4.29, p=3.8·10-17) with the risk of MS in the Novosibirsk region population. The study demonstrated a significant effect of genetic factors on phenotypic expression of MS: an C allele of rs6074022 polymorphism (CD40) was associated with a higher rate of MS progression, and the TT genotype of rs1535045 was associated with a slower progression of MS and early MS onset. A more benign course and a higher frequency of an T allele of rs3135388 (44% vs 33%, p=0.003) was found in familial cases compared to sporadic cases. The further specific research is needed for understanding the genetic basis of susceptibility to MS.
Assuntos
Antígenos CD40/genética , DNA/genética , Predisposição Genética para Doença , Cinesinas/genética , Esclerose Múltipla/genética , Polimorfismo Genético , Adulto , Alelos , Progressão da Doença , Feminino , Frequência do Gene , Genótipo , Humanos , Masculino , Fenótipo , Reação em Cadeia da Polimerase , Recidiva , Fatores de RiscoRESUMO
The aim of our study was to investigate the effect of recombinant human cytokine EMAP II (endothelial monocyte-activating polypeptide II) on the expression of MGMT gene, encoding repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) in human cell cultures. The influence of EMAP II on cell proliferation was performed using routine MTT assay. Identification of MGMT in cell extracts was performed using Western blot analysis. We used cell lines: A102 (fibroblasts), CB-1 (umbilical cord blood stromal cells), 4BL6 (cells derived from peripheral blood). It was shown that cytokine EMAP II caused induction of MGMT expression in studied human cell lines. There was a decrease in cell number at high concentrations of this cytokine. It was found that the presence of cytokine EMAP II in serum-free growth medium leads to increasing of repair enzyme MGMT expression level in human cells in vitro.
Assuntos
Antineoplásicos Alquilantes/efeitos adversos , Sobrevivência Celular/efeitos dos fármacos , Citocinas , Reparo do DNA/efeitos dos fármacos , Expressão Gênica/efeitos dos fármacos , Proteínas de Neoplasias , O(6)-Metilguanina-DNA Metiltransferase/metabolismo , Proteínas de Ligação a RNA , Antineoplásicos Alquilantes/administração & dosagem , Western Blotting , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Meios de Cultura Livres de Soro , Citocinas/farmacologia , Citocinas/uso terapêutico , Dano ao DNA/efeitos dos fármacos , Indução Enzimática/efeitos dos fármacos , Sangue Fetal/citologia , Fibroblastos/citologia , Fibroblastos/efeitos dos fármacos , Fibroblastos/metabolismo , Guanina/análogos & derivados , Guanina/metabolismo , Hepatócitos/citologia , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , Humanos , Metilação , Proteínas de Neoplasias/farmacologia , Proteínas de Neoplasias/uso terapêutico , Neoplasias/tratamento farmacológico , Neoplasias/patologia , O(6)-Metilguanina-DNA Metiltransferase/genética , Proteínas de Ligação a RNA/farmacologia , Proteínas de Ligação a RNA/uso terapêutico , Células Estromais/citologia , Células Estromais/efeitos dos fármacos , Células Estromais/metabolismoRESUMO
A stable increase in the frequency of methicillin resistant clinical isolates of staphylococci was recorded. 258 strains of Staphylococcus aureus and S. epidermidis, including methicillin resistant ones, were susceptible to batumin. The minimum inhibitory concentration of batumin ranged within 0.04 and 0.5 mcg/ml and depended on the concentration of the microbial cells and the medium pH. The medium composition had limited influence on the batumin activity. No differences in the batumin activity against methicillin susceptible and methicillin resistant staphylococci were observed. The antibiotic had bactericidal action on the strains (2-4 mcg / ml). The results of the study showed that batumin ointment was prospective for eradication of S. aureus. including MRSA, in cases with the nasal carriage and for control of multiresistant strains during hospital outbreaks.
